TWiV 901: COVID-19 clinical update #115 with Dr. Daniel Griffin

In COVID-19 clinical update #115, Dr. Griffin reviews cross-variant immunity without vaccination, EUA for boosters in 5-11 year olds, B.1.1.529 attack rate, scent dogs, Omicron and pets, Paxlovid, Veklury, Fluvoxamine, antigen positivity after isolation, inflammasome activation and severe disease, and GI persistence and fecal shedding. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Limited cross-variant immunity without vaccination (Nature) EUA for boosters in 5-11 year olds (FDA) Stages of COVID-19 (AIDS Rev) B.1.1.529 attack rate in Australia (JID) Scent dogs (BMJ) Does Omicron affect pets? (CVMBS News) Paxlovid eligibility checklist (FDA) Supratherapeutic tacrolimus with nirmatrelvir/ritonavir (Op For Inf Dis) Is longer Paxlovid needed? (Reuters) How about Veklury? (Gilead) Fluvoxamine declined (FDA) Antigen positivity after isolation (MMWR) Inflammasome activation drives COVID-19 pathology (TWiV 900, Nature) PASC and viral antigen persistence in gut (Gastroenterol) GI symptoms and fecal shedding (Med) Contribute to ASTMH fundraiser at PW Dr. Griffin’s treatment guide (pdf) Letters read on TWiV 901 Timestamps by Jolene. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]